Cargando…

Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension

PURPOSE: To evaluate the efficacy of Pelvicol xenograft use during abdominal sacrocolpopexy to repair pelvic organ prolapse (POP). PATIENTS AND METHODS: A total of 27 consecutive women with symptomatic POP were included in this study. A POP-quantification system and International Continence Society...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijazi, Sameh, Echtle, Dieter, Aboumarzouk, Omar M, Heinrich, Elmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593406/
https://www.ncbi.nlm.nih.gov/pubmed/28919825
http://dx.doi.org/10.2147/IJWH.S134239
_version_ 1783263028305723392
author Hijazi, Sameh
Echtle, Dieter
Aboumarzouk, Omar M
Heinrich, Elmar
author_facet Hijazi, Sameh
Echtle, Dieter
Aboumarzouk, Omar M
Heinrich, Elmar
author_sort Hijazi, Sameh
collection PubMed
description PURPOSE: To evaluate the efficacy of Pelvicol xenograft use during abdominal sacrocolpopexy to repair pelvic organ prolapse (POP). PATIENTS AND METHODS: A total of 27 consecutive women with symptomatic POP were included in this study. A POP-quantification system and International Continence Society classification were used. Functional and anatomical outcomes were assessed. Subjective outcomes and physical activity after surgery were evaluated due to modified quality of life questionnaire. RESULTS: Median follow-up was 21 months (range: 16 to 41 months). Twenty-four (89%) patients were available for anatomical and subjective evaluation. Preoperative POP-quantification classification was: stage I: 11.1%, stage II: 25.9%, stage III: 48.2%, and stage IV: 14.8%. Overall, pad usage significantly decreased (mean 4.8 vs 1 pads, P=0.001). Stress urinary incontinence significantly improved after surgery in nine women (P=0.001). An additional five women were completely continent. No de-novo incontinence developed. Six women with preoperative urinary retention improved in the amount of residual urine postoperative (mean 35 vs 165 mL). Failure rate was 8.3% at 3 and 11 months after surgery, requiring a second reconstruction. There was no graft related complications or graft rejections necessitating removal occurring. Response rate of the questionnaire was 67%. Two women reported no interference in physical activity after 2 postoperative months, five women after 5 months, and five women 1 year later. Pelvic pain (vaginal pain) was partly improved in eight patients, postoperatively, and ten patients had complete resolution of pain after surgery. CONCLUSION: This study demonstrates that abdominal sacrocolpopexy is an effective surgical treatment in correcting POP. The use of Pelvicol is associated with a high recurrence rate and increased failure rate compared to traditional sacrocolpopexy with mesh. Larger clinical trials to evaluate the functional and anatomical outcomes are needed.
format Online
Article
Text
id pubmed-5593406
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55934062017-09-15 Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension Hijazi, Sameh Echtle, Dieter Aboumarzouk, Omar M Heinrich, Elmar Int J Womens Health Original Research PURPOSE: To evaluate the efficacy of Pelvicol xenograft use during abdominal sacrocolpopexy to repair pelvic organ prolapse (POP). PATIENTS AND METHODS: A total of 27 consecutive women with symptomatic POP were included in this study. A POP-quantification system and International Continence Society classification were used. Functional and anatomical outcomes were assessed. Subjective outcomes and physical activity after surgery were evaluated due to modified quality of life questionnaire. RESULTS: Median follow-up was 21 months (range: 16 to 41 months). Twenty-four (89%) patients were available for anatomical and subjective evaluation. Preoperative POP-quantification classification was: stage I: 11.1%, stage II: 25.9%, stage III: 48.2%, and stage IV: 14.8%. Overall, pad usage significantly decreased (mean 4.8 vs 1 pads, P=0.001). Stress urinary incontinence significantly improved after surgery in nine women (P=0.001). An additional five women were completely continent. No de-novo incontinence developed. Six women with preoperative urinary retention improved in the amount of residual urine postoperative (mean 35 vs 165 mL). Failure rate was 8.3% at 3 and 11 months after surgery, requiring a second reconstruction. There was no graft related complications or graft rejections necessitating removal occurring. Response rate of the questionnaire was 67%. Two women reported no interference in physical activity after 2 postoperative months, five women after 5 months, and five women 1 year later. Pelvic pain (vaginal pain) was partly improved in eight patients, postoperatively, and ten patients had complete resolution of pain after surgery. CONCLUSION: This study demonstrates that abdominal sacrocolpopexy is an effective surgical treatment in correcting POP. The use of Pelvicol is associated with a high recurrence rate and increased failure rate compared to traditional sacrocolpopexy with mesh. Larger clinical trials to evaluate the functional and anatomical outcomes are needed. Dove Medical Press 2017-09-06 /pmc/articles/PMC5593406/ /pubmed/28919825 http://dx.doi.org/10.2147/IJWH.S134239 Text en © 2017 Hijazi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Hijazi, Sameh
Echtle, Dieter
Aboumarzouk, Omar M
Heinrich, Elmar
Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension
title Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension
title_full Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension
title_fullStr Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension
title_full_unstemmed Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension
title_short Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension
title_sort abdominal sacrocolpopexy with pelvicol xenograft and concomitant burch colposuspension
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593406/
https://www.ncbi.nlm.nih.gov/pubmed/28919825
http://dx.doi.org/10.2147/IJWH.S134239
work_keys_str_mv AT hijazisameh abdominalsacrocolpopexywithpelvicolxenograftandconcomitantburchcolposuspension
AT echtledieter abdominalsacrocolpopexywithpelvicolxenograftandconcomitantburchcolposuspension
AT aboumarzoukomarm abdominalsacrocolpopexywithpelvicolxenograftandconcomitantburchcolposuspension
AT heinrichelmar abdominalsacrocolpopexywithpelvicolxenograftandconcomitantburchcolposuspension